Proteo Inc./Proteo Biotech AG: Start of the Phase II Clinical Trial With Elafin

IRVINE, Calif./Kiel, GERMANY--(BUSINESS WIRE)--Proteo Inc. (OTCBB: PTEO; WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG announced today the beginning of patient recruitment for a Phase II clinical trial. In this randomized, placebo-controlled Phase II trial the effect of Elafin on inflammatory parameters will be investigated in patients undergoing esophagectomy for esophagus carcinoma. The trial will be performed under the direction of Prof. Fred Fändrich, Department of General and Thoracic Surgery, University of Kiel: »The removal of the esophagus for esophageal cancer is a very invasive surgical procedure that frequently requires long stays in intensive care units. No drugs are currently available which substantially alleviate the inflammatory reaction of the body to this surgical treatment. I am therefore particularly pleased that we have the opportunity to conduct the first clinical trial worldwide on the therapeutic efficacy of the drug candidate Elafin.